Our Scientific Advisory Board


We are supported by a Scientific Advisory Board (SAB), composed of an international group of neuroscientists and neurologists with particular expertise in Spinal Muscular Atrophy research. The SAB advises us on research grant applications and clinical trials initiatives which aim to:

SMA Europe SAB & scientific administrators

SMA Europe SAB & scientific administrators

Brunhilde Wirth

PhD (Chair)

Professor of Human Genetics and Director of the Institute of Human Genetics at the Medical Faculty of the University of Cologne, Germany.

Laurent Servais

Laurent Servais

MD, PhD (vice-Chair)

Professor Servais graduated from Louvain Medical School (Belgium) in 1999. He obtained a PhD in Neuroscience in 2005 from the Free University of Brussels (ULB), Belgium. He became a Child Neurologist in 2006 at the Free University of Brussels (ULB) then a Resident in child neurology in the Robert Debré Hospital in Paris, until 2008 when he was appointed as a Child Neurologist at the Institut de Myologie in November 2008. Laurent is now Professor of Paediatric Neuromuscular Diseases at the University of Oxford and Invited Professor of Child Neurology at the University of Liège in Belgium.

Enrico Bertini


Paediatric Neurologist, Head of the Unit of Neuromuscular and Neurodegenerative Disorders at the Bambino Gesu’ Children’s Research Hospital in Rome, and Contract Professor in Neurogenetic disorders at the School of Clinical Genetics of the Catholic University of Rome.

Serge Braun

PharmD, PhD

Scientific Director of AFM (Association Française contre les Myopathies), France.

Arthur Burghes


Professor at the Center for Muscle Health & Neuromuscular Disorders, The Ohio State University/ Nationwide Children’s Hospital, Columbus, Ohio, USA.

Stefania Corti


Dr. Stefania Corti is a neurologist in Milan, Italy. She is an Associate Professor of Neurology and PI of Neural Stem Cell Lab at the University of Milan. She is the co-supervisor of the motor neuron out-patient service and member of neuromuscular team at the IRCCS Foundation Ca’ Granda University of Milan. Corti’s main research interests are stem cell/molecular therapies for the treatment of motor neurons diseases, in particular, Spinal Muscular Atrophy (SMA), Spinal Muscular Atrophy with respiratory distress type I (SMARD1), and Amyotrophic Lateral Sclerosis (ALS).
After Board Certification in Neurology, she obtained a PhD in Molecular Medicine at the University of Milan. Since 2004, up to now, she has worked first as research collaborator, then as Assistant Professor and from 2015 as Associate Professor at the University of Milan. In 2014 she obtained the habilitation as Associate Professor and as Full Professor of Neurology. She is a member of the Board of the PhD School of Molecular Medicine and of the Dino Ferrari Center Scientific Committee. The scientific results of Dr. Corti, basic and clinical research have been published in high citation rating peer reviewed journals (>130 articles).

Richard Finkel


Paediatric Neurologist and Division Chief of the Division of Neurology, Department of Paediatrics at Nemour’s Children’s Hospital in Florida, USA.

Tom Gillingwater


Professor Gillingwater is Professor of Neuroanatomy at the University of Edinburgh and Editor-in-Chief of the Journal of Anatomy and Academic Editor of PLoS One. He also teaches gross human anatomy and neuronanatomy to medical students and MSc students.

Cécile Martinat


Dr. Martinat obtained her PhD in 2001 at the Pasteur Institute in the laboratory of Michel Brahic on the cellular mechanisms involved in the persistence of Theiler’s virus within the central nervous system. For her post-doctoral formation, she joined in 2001 the laboratory of Pr. A. Abeliovich at Columbia University to evaluate the potential offered by mouse and human pluripotent stem cells to explore the mechanisms involved in Parkinson Disease. They identified two transcription factors that play a key role in the specification of dopamine neurons and present consequently a therapeutic potential for this neurodegenerative disease. For her return to France in 2005, she naturally decided to join the first institute in France, I-STEM, created by Marc Peschanki, dedicated to the use of human pluripotent stem cells to study and treat monogenic diseases. After two years dedicated to the use of human embryonic stem cells to model neuromuscular diseases, she was appointed by INSERM as a permanent researcher and obtained from the Genopole an ATIGE program to further develop her research in I-STEM. Research projects developed by her group mainly focus on the use of human pluripotent stem cells for pathological modeling of neuromuscular diseases and consequently the development of adapted drug screenings. In particular, her group recently demonstrated that human embryonic stem cells carrying the causal mutation for Myotonic Dystrophy type 1 (DM1) can be used to identify new pathological mechanisms, and discover new therapeutic strategies. In parallel to DM1, they recently developed a new protocol to efficiently and rapidly convert human pluripotent stem cells into synchronous populations of spinal motoneurons and use this development to expend our research on other neuromuscular diseases characterised by the specific death of motoneurons. In 2005, she also took the head of INSERM/UEVE UMR 861 in I-STEM.

Eduardo Tizzano


Paediatrician & Medical Geneticist, Director of the Department of Clinical and Molecular Genetics and Unit of Rare Diseases, Hospital Universitari Valle Hebrón, Barcelona, Spain.

Ludo Van der Pol


Ludo van der Pol, MD PhD is a Neurologist, Associate Professor of Neurology and head of the Netherlands SMA center at the University Medical Center Utrecht (UMCU) in The Netherlands

Ulrika Kreicbergs


Professor Ulrika Kreicbergs holds a professorship in palliative care for children and youth at Ersta Sköndal University College and is also associated to the Karolinska Institutet in Stockholm, Sweden.

Her research on families affected by cancer has been acknowledged worldwide. She received the prestigious Schweisguth Prize – SIOP, the International Society of Paediatric Oncology in 2004. Dr Kreicbergs did her postdoc at Dana Farber Cancer Institute and Boston Children’s Hospital in Boston, US. Dr Kreicbergs has continued her research on the child and family in palliative care. Her work is focused on factors in the health care that can be modified or avoided to reduce suffering and thereby enhance quality of life for the child and their families.

The SAB is supported by 2 scientific administrators, who jointly manage the Call for Research Proposals as well as other scientific initiatives: